Germitec Expands Business With €11 Million Financing Round

Germitec, a global healthcare leader in designing and commercializing high-Level UV-C disinfection systems for ultrasound probes, radically simplifying the lives of healthcare professionals in terms of safety, time, and responsibility, today announces the completion of a financing round of €11M and the appointment of its new management team.


New Shareholders

Winner of the Prix Galien in 2020 for the best medical device2, Germitec has secured a strong financing plan with its new shareholders: Financière Arbevel, Sham Innovation Santé advised by Turenne Capital, Kurma Partners and funds based in Nouvelle-Aquitaine as well as private investors. This finance round is a strong commitment and a validation of the market potential of the UV-C-based high-level disinfection (HLD) technology and devices that Germitec has developed and commercialized.


Ambitious International Expansion

The main objective of this new financing round is to launch an ambitious international commercial expansion plan aiming at transforming the historically technology-driven company into a leading sales company with an international footprint in strategic markets. Germitec is actively working towards obtaining FDA clearance in the coming months to commercialize Hypernova Chronos in the USA, the pioneering market of HLD, recommended since 2008 by the Center for Disease Control and Prevention (CDC). Beyond this expansion, the Company will continue to structure its operations and lead innovation in the ultrasound probe HLD market.

“With the support of our historical and new shareholders, I am confident we will rapidly transform Germitec into a high-growth commercial company that supports healthcare professionals around the world on a daily basis to ensure the safety of their patients during ultrasound examinations. This is the mission of this new management team, and we will strive to achieve it as we have done before in other leading medical device companies,” said Vincent Gardès, CEO of Germitec.

“On behalf of the new shareholders, we are very excited to be involved in this project. We were very impressed and quickly convinced by the work accomplished by Germitec and the great opportunity that can be materialized with this financing. Providing healthcare professionals and patients with innovative, safe, and simple solutions for the major problem of cross-infection in healthcare facilities is the cornerstone of our commitment. We are confident that the new management team will make a strong impact and deliver on Germitec’s mission,” said Louis Geslin, co-Manager of the Arbevel Life Sciences Crossover fund.

“We are delighted and honored to welcome new shareholders and to appoint this new management team. This validates all the efforts the Germitec teams have made since its inception to develop products and technology with recognized potential,” said Clément Deshays, Chairman of the Board of Germitec.

The New Management Team

As part of this financing round, a new management team has been appointed with the aim to support and accelerate Germitec’s development and drive its long-term strategy:

Vincent Gardès, CEO and Board Member:
Vincent has 25 years of successful experience in the medical device industry, both in large international companies (Medtronic, Stryker, Bard) and in the development of innovative startups (Vexim, Kumovis, Amber Implants). Vincent brings solid expertise in International and European sales, marketing, human resources, and experience in financial management (IPO, secondary offerings, merger, and acquisitions). Among his successes, Vincent was instrumental in Stryker’s acquisition of Vexim (specialist in the treatment of vertebral compression fractures with its SpineJack® device) at the end of 2017 for €183M. He recently supported the acquisition of Kumovis by 3D Systems (price undisclosed).

José Da Gloria, Deputy CEO, and Chief Financial Officer: José has more than 20 years of successful experience in finance acquired both in large corporations (Dell, ev3 acquired by Covidien) and in medical device and biotech start-ups, with a successful track record in building and leading large financial transactions. José also strongly contributed to the successful acquisition of Vexim by Stryker. At GERMITEC, José will oversee the financial performance as well as all administrative, HR, and strategic project developments. 

Arnaud Casson, Chief Operations Officer:
Arnaud started his career as a financial auditor at EY. Over the past 20 years, he built up his experience within the Stryker group and more particularly in support of the Spine Division, where he progressed to supply chain and operations management roles. For the past 8 years, he has been responsible for the Spine division’s manufacturing facilities based in Europe. Arnaud has contributed to improving operational efficiency and reducing manufacturing costs whilst putting customers first. At GERMITEC, Arnaud will lead operational activities, covering R&D, quality assurance, regulatory affairs, and supply chain.


Within the framework of this new organization, a new Board of Directors has been constituted as follows:

Clément Deshays: Former CEO and co-founder of GERMITEC will be non-executive Chairman of the Board 

Louis Geslin: Board member, representing Financière Arbevel 

Bervin Bouani: Board member, representing Turenne Capital 

Jean-Francois Rivassou: Board member, representing Kurma Partners 

Patrice Taisson: CEO of Softway Medical, independent Board member 

Vincent Gardès: CEO, Board member 

Claudia Daugan (Galia): Observer


TP ICAP MIDCAP’s teams have advised Germitec for the addition of Financière Arbevel and Sham Innovation Santé advised by Turenne Capital as equity partners. Degroux Brugère (Jérémie Swiecznik, Benoît Courtet) and Mermoz (Tristan Segonds et Éléanore Griffiths) law firms also advised the new investors.

On the legal aspects, Germitec was also assisted by the Goodwin firm: Anne-Charlotte Rivière (partner), Aude Steinberg (associate), Coralie Davis (paralegal), and the law firm Fidufrance.


About Germitec

Germitec is committed to providing healthcare professionals and patients with safe, simple, and automated UV-C solutions for ultrasound probe disinfection, replacing chemistry with photons to radically simplify the lives of healthcare professionals in terms of safety, time, and liability.

With 15 years of experience in the design and development of sustainable hospital hygiene solutions, GERMITEC is a market leader with a proven track record of product development and sales growth and strong prospects for expansion.

About Germitecs’s Product Lines

GERMITEC automated systems replace impregnated chemical wipes, soaking stations, and the use of hydrogen peroxide with a faster, simpler, and cleaner automated system for a seamless high-level disinfection (HLD) process for ultrasound probes.

Hypernova Chronos, dedicated to external, vaginal, and rectal ultrasound probes, offers ultrafast HLD in 90 seconds with digital traceability. This chemical-free system is changing clinical practice, enabling UV-C HLD to become the standard of care in all hospital and clinical departments. Hypernova Chronos received the 2020 Prix Galien Award in the “Best Medical Device” category.

Antigermix AE1, dedicated to transesophageal (TEE) ultrasound probes, is designed to ensure that the entire length of the TEE probe, including the handle, is disinfected in just 3 minutes, using UV-C light.

PROUV is an advanced digital traceability system designed to be used with Germitec’s HLD automated systems. PROUV offers a new level of compliance and security for advanced digital traceability, ensuring quality health outcomes and improving workflow efficiency when using ultrasound scanners.

Hypernova Chronos and Antigermix AE1 are approved in over 35 countries worldwide, covering Asia, the Middle East, Europe, and the Americas.

About Healthcare-Acquired Infections (HAI)

The CDC defines healthcare-acquired infections (HAI) as an infectious event that is diagnosed more than 48 hours after admission to a healthcare facility or examination, without evidence that the pathogen was already in the incubation phase. HAI include hospital-acquired infections (also called Nosocomial Infections) but also infections that could have been contracted in other healthcare settings.

The 2017 National Prevalence Survey conducted in France confirmed that the prevalence of hospital-acquired infections represents approximately 5% of all patients hospitalized in a year.

A large retrospective study conducted between 2010 and 2016 in Scotland found an association between low-level disinfection procedures and the occurrence of infection. Compared with unexposed patients, those who underwent transesophageal, transvaginal, or transrectal ultrasound were more likely to develop an infection that eventually led to the prescription of antibiotics3.

Without proper disinfection, as outlined in the Spaulding classification4, routine examinations can put patients’ health at risk, including long-term HPV infections5.


Vincent Gardès, CEO

Media Relations: ATCG PARTNERS
Marie Puvieux / Jérôme Marino
+33 (0)6 10 54 36 72 / +33 6 11 56 98 91

Click here - download press release